Related Experiment Video

Updated: Dec 5, 2025

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

11.1K

Modulation of Inflammasome and Pyroptosis by Olaparib, a PARP-1 Inhibitor, in the R6/2 Mouse Model of Huntington's

Emanuela Paldino1, Vincenza D'Angelo2, Daunia Laurenti1

  • 1Laboratory of Neuroanatomy, IRCCS Fondazione Santa Lucia, 00143 Rome, Italy.

Cells
|October 17, 2020
PubMed

Insights

Olaparib, a PARP-1 inhibitor, shows neuroprotective effects in a mouse model of Huntington's disease (HD). This drug improved survival and neurological function by modulating inflammasome activation, suggesting its potential for HD therapy.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cell Biology

Background:

  • Pyroptosis, a caspase-1 (Casp-1) dependent cell death, is implicated in Huntington's disease (HD).
  • PARP-1 inhibitors have previously demonstrated beneficial effects in HD models.

Purpose of the Study:

  • To investigate the neuroprotective potential of Olaparib, a PARP-1 inhibitor, in a mouse model of Huntington's disease.
  • To evaluate Olaparib's impact on survival, neurological deficits, and the inflammasome pathway in HD.

Main Methods:

  • Administration of Olaparib or vehicle to R6/2 mice from pre-symptomatic to late stages.
  • Assessment of clinical effects through behavioral studies.
  • Evaluation of neuroprotection and neuronal death pathways via immunohistochemistry and Western blotting.

Main Results:

  • Olaparib treatment significantly increased survival rates in HD mice.
  • Neurological deficits were ameliorated, and clinical outcomes improved in neurobehavioral tests.
  • Olaparib modulated inflammasome activation, suggesting a key mechanism for its neuroprotective effects.

Conclusions:

  • Olaparib demonstrates significant neuroprotective effects in a mouse model of Huntington's disease.
  • The drug's mechanism involves modulating inflammasome activation.
  • Olaparib, an existing anti-neoplastic drug, shows promise as a therapeutic agent for Huntington's disease.
Keywords:
Huntington’s diseaseInflammasomeNLRP3Parp-1 inhibitionPyroptosiscaspase-1microglia

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.2K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.3K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.9K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.9K